JP2024506954A - ワクチン作製用の遺伝子改変細菌 - Google Patents

ワクチン作製用の遺伝子改変細菌 Download PDF

Info

Publication number
JP2024506954A
JP2024506954A JP2023549900A JP2023549900A JP2024506954A JP 2024506954 A JP2024506954 A JP 2024506954A JP 2023549900 A JP2023549900 A JP 2023549900A JP 2023549900 A JP2023549900 A JP 2023549900A JP 2024506954 A JP2024506954 A JP 2024506954A
Authority
JP
Japan
Prior art keywords
cancer
bacteria
vaccine
tumor
associated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506954A5 (https=
Inventor
ラヴィッド シュトラウスマン
オデッド サンドラー
レウト リフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2024506954A publication Critical patent/JP2024506954A/ja
Publication of JP2024506954A5 publication Critical patent/JP2024506954A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023549900A 2021-02-18 2022-02-17 ワクチン作製用の遺伝子改変細菌 Pending JP2024506954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150681P 2021-02-18 2021-02-18
US63/150,681 2021-02-18
PCT/IL2022/050191 WO2022175951A1 (en) 2021-02-18 2022-02-17 Genetically modified bacteria for generating vaccines

Publications (2)

Publication Number Publication Date
JP2024506954A true JP2024506954A (ja) 2024-02-15
JP2024506954A5 JP2024506954A5 (https=) 2025-02-25

Family

ID=80623424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549900A Pending JP2024506954A (ja) 2021-02-18 2022-02-17 ワクチン作製用の遺伝子改変細菌

Country Status (6)

Country Link
US (1) US20240009286A1 (https=)
EP (1) EP4294429A1 (https=)
JP (1) JP2024506954A (https=)
CA (1) CA3208536A1 (https=)
IL (1) IL305314A (https=)
WO (1) WO2022175951A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295726A (en) 2022-08-17 2024-03-01 Yeda res & development co ltd Genetically modified bacteria for generating vaccines
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor
WO2025177207A1 (en) * 2024-02-21 2025-08-28 Baccine Ltd Inducible immunomodulating tumor-homing bacteria

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049036A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1943344A2 (en) * 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
KR100985914B1 (ko) * 2006-12-13 2010-10-08 주식회사 바이오리더스 간암 특이 항원인 알파­페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물
EP2604682A1 (en) * 2011-12-12 2013-06-19 Universite Joseph Fourier - Grenoble 1 Attenuated and adapted strain of pseudomonas for delivering antigens
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
EP3406731A1 (en) 2017-05-22 2018-11-28 Commissariat à l'Energie Atomique et aux Energies Alternatives Metabolic labeling of bacterial teichoic acids cell wall

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049036A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy

Also Published As

Publication number Publication date
WO2022175951A1 (en) 2022-08-25
EP4294429A1 (en) 2023-12-27
CA3208536A1 (en) 2022-08-25
IL305314A (en) 2023-10-01
US20240009286A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
Lam et al. An empirical antigen selection method identifies neoantigens that either elicit broad antitumor T-cell responses or drive tumor growth
JP2024506954A (ja) ワクチン作製用の遺伝子改変細菌
Riker et al. Immune selection after antigen-specific immunotherapy of melanoma
Guo et al. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine
KR20140134695A (ko) 리스테리아 백신 치료 후 억제 세포 기능 저해
KR20140054140A (ko) 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
JP7098599B2 (ja) 癌免疫療法用のｄｎａワクチンの製造方法
Shukla et al. Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses
JP2020120681A (ja) ＨＡＡＨ（アスパルチル−（アスパラギニル）−β−ヒドロキシラーゼ）を標的とする治療用癌ワクチン
CN112533630A (zh) 用于癌症的个体化疫苗
JP2025131713A (ja) Ｈｐｖ免疫療法
Xu et al. Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination
CN108484776A (zh) 一种融合蛋白、制备方法及其应用
Olin et al. Superior efficacy of tumor cell vaccines grown in physiologic oxygen
KR20150037953A (ko) 항종양제, 종양 검출용 마커 및 경구 백신제
JP2024506955A (ja) ワクチンを作製する方法
US20260048107A1 (en) Genetically modified bacteria for generating vaccines
Nabeta et al. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line
Chu et al. Combined immunization against TGF-β1 enhances HPV16 E7-specific vaccine-elicited antitumour immunity in mice with grafted TC-1 tumours
AU2005306186B2 (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
CN111334521B (zh) 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法
CN102775501B (zh) 用于肿瘤治疗的白细胞介素21(il-21)药物
de Jong et al. A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
Yao et al. Expansion of tumor-infiltrating lymphocytes with substantial stem cell properties from vulvar cancer
CN120265755A (zh) 用于疾病治疗的t细胞-nk细胞相互作用抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231016

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203